ストックスクリーナーアプリを入手
7.62
0.00%
0.70
前日終値:
$8.32
開ける：
$8.27
24時間の取引高:
9,677
Relative Volume:
0.59
時価総額：
$59.01M
収益：
$28.83M
当期純損益:
$-13.34M
株価収益率:
-5.0132
EPS:
-1.52
ネットキャッシュフロー:
$-7.49M
1週間 パフォーマンス:
-10.92%
1か月 パフォーマンス:
-17.30%
6か月 パフォーマンス:
-52.62%
1年 パフォーマンス:
+404.24%
1日の値動き範囲:
$7.53
$8.27
1週間の範囲:
$7.53
$9.7465
52週間の値動き範囲:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
XCUR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.3888 | 544.73M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.74 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.148 | 316.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.735 | 118.42M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.9912 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 開始されました | BMO Capital Markets | Outperform |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
Exicure Inc (XCUR) 最新ニュース
Exicure (NASDAQ:XCUR) Stock Price Down 5.8% – Here’s Why - Defense World
What's Going On With Exicure Shares Monday? - MSN
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
XCURExicure, Inc. Reports Full Year 2024 Financial Results - mx.advfn.com
Exicure faces Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
(XCUR) Trading Report - news.stocktradersdaily.com
Exicure Receives Nasdaq Delinquency Notification - TipRanks
Exicure faces Nasdaq non-compliance notice - Investing.com Australia
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q | XCUR Stock News - GuruFocus
Exicure Receives Noncompliance Notice From Nasdaq - marketscreener.com
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report | XCUR Stock News - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
Exicure (NASDAQ:XCUR) Trading Down 4.5% – Here’s Why - Defense World
Exicure (XCUR) Is Paying a $5.6M Settlement to Investors — Here’s How to Get Your Share - TradingView
Exicure Delays 10-Q Filing Amid Acquisition - TipRanks
(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com
Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria
Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks
Exicure enters strategic convertible bond agreement - Investing.com
Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Breakthrough: New Multiple Myeloma Treatment Achieves Perfect Success Rate in Trial - Stock Titan
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com
Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Growth in Short Interest - The AM Reporter
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks
HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada
HiTron Systems acquires $8.7 million in Exicure stock - Investing.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire
Exicure Inc (XCUR) 財務データ
収益
当期純利益
現金流量
EPS
Exicure Inc (XCUR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DGP Co., Ltd. | 10% Owner |
Sep 12 '24 |
Buy |
3.00 |
237,223 |
711,669 |
849,223 |
2.32%
0.98%
大文字化:
|
ボリューム (24 時間):